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performed to determine if gender was an independent predictor of guideline door-to-
balloon time of <90 min.
Results: Amongst 2032 pts with confirmed STEMI referred between May 2005 and
July 2010, 574 (28%) were women and 1458 (72%) were men. Women differed from
men in the following baseline characteristics: age, 68±14 vs. 60±12, p<0.0001,
hypertension, 58% vs. 45%, p<0.0001, smoking, 34% vs. 44%, p<0.0001, prior bypass
surgery, 2% vs. 4%, p=0.01, prior stroke, 9% vs. 6%, p=0.01, systolic blood pressure,
132±30 vs 136±29, p=0.001, BMI, 27±6 vs. 28±5, p=0.02, creatinine clearance, 65±28
vs. 76±29, p<0.0001, and Killip class 1 82% vs. 87%, p=0.008. Women were more
likely to call for an ambulance, 71% vs. 62%, p=0.0001. PCI was performed in 92%
of women and 94% of men, p=0.17. Women were less likely to be treated with stents,
88% vs. 92%, p=0.007. The median door-to-balloon time in women was 105 min
(IQR=79-137) vs. 99 min (IQR= 72-132) for men, p=0.005. The 30 day mortality was
7.5% in women vs. 4.8% in men, p=0.02. The results of the multivariable analysis to
determine predictors of door-to-balloon time <90 min are shown in the table.
Conclusion: In spite of standardized protocols implemented in a STEMI system,
women continue to have longer door-to-balloon times. Additional research is needed
to reduce delays to reperfusion in women.
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TCT-426
Diabetes Mellitus Requiring Insulin and High Residual Platelet Reactivity After
Clopidogrel Loading Dose are Predictors of Long-term Clinical Outcome in
Patients with Acute Coronary Syndrome: the RECLOSE2-ACS Diabetes
Mellitus Substudy
Renato Valenti, Angela Migliorini, Guido Parodi, Rossella Marcucci, Piergiovanni
Buonamici, Giampaolo Cerisano, Rosanna Abbate, Gianfranco Gensini, David
Antoniucci
Division of Cardiology, Careggi Hospital, Florence, Italy
Background: The Responsiveness to CLOpidogrel and Stent-related Events in patients
with ACS(RECLOSE2-ACS) receiving PCI and for whom platelet reactivity after
clopidogrel loading was prospectively assessed. To test if high residual platelet
reactivity (HRPR) would be a prognostic marker of risk of thrombotic events and to
assess the relationship of diabetes mellitus (DM) with HRPR on clinical outcome.
Methods: Consecutive ACS patients undergoing PCI and platelet reactivity after 600
mg clopidogrel loading dose. Patients with HRPR (ADP 10 μmol ≥ 70%) received an
increased chronic dose of clopidogrel. DM was investigated according to insulin use.
The interaction between DM and HRPR on outcome was assessed by Cox analysis.
Primary end point: composite of cardiac death, MI, urgent PCI, and stroke at 2y FU.
ClinicalTrial.gov: NCT01231035.
Results: A total of 1789 patients were enrolled: 20% had DM: 11% were non-insulin
dependent (NIDD), 9% were insulin dependent (IDD) and 80% were non diabetic
(ND). HRPR incresead according to diabetic status: ND 12%, NIDD 18% and IDD
22% (p=.001). Most patients with HRPR remained with an ADP ≥ 70% after treatment
adjustment: ND 36%, NIDD 41% and IDD 43%. In patients with DM and HRPR, there
were no differences in the primary end point rate (15% vs 19%) after treatment
adjustment between patients with an ADP < 70% and with ADP ≥ 70%. HRPR and
IDD resulted independent predictors of the primary end point (HR 1.5 ; p=.032 and
HR 1.4; p=.029 respectively) and cardiac mortality (HR 1.7; p=.013 and HR 1.8;
p=.016). No interaction of HRPR with DM on outcome was found.
Conclusion: HRPR is two-fold higher in IDD as compared to ND. HRPR and IDD
are predictors of long-term clinical outcome in ACS patients receiving PCI. In DM
patients, treatment adjustment with first generation of thienopiridine, has not impact
on outcome. It is unknown if new antithrombotic agents (as prasugrel or ticagrelor)
will provide an improvement on clinical outcome.
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Clopidogrel Hyporesponsiveness, Interacting with Diabetes Mellitus, Predicts 2-
Year Cardiovascular Outcome Among Taiwanese Population Underging
Percutaneous Coronary Intervention
Ping-Yen Liu1, 2, Ling-Jay Hsu3, Po-Tseng Lee1, 2, Cheng-Hann Lee1, Ju-Yi Chen1, 2,
Yi-Heng Li1, Liang-Miin Tsai1, Jyh-Hong Chen1
1Division of Cardiology, Internal Medicine, National Cheng Kung University
Hospital, Tainan, Taiwan; 2Institute of Clinical Medicine, National Cjeng Kung
University, Tainan, Taiwan; 3College of Medicine, National Cheng Kung University,
Tainan, Taiwan
Background: Platelet reactivity after clopidogrel therapy varies among individuals.
This study was aimed to evaluate clinical impacts of clopidogrel response variability
and the covariant factors in Asian populations undergoing elective percutaneous
coronary intervention (PCI).
Methods: Patients receiving clopidogrel after elective PCI were prospectively followed
up. Platelet reactivity after clopidogrel therapy was measured with the VerifyNow
P2Y12 assay. The primary endpoints were stent thrombosis and the composite of
cardiac death and non-fatal myocardial infarction (MI) at 2 year.
Results: Among 160 patients (average year of age 62.1±12.9 with 83.5% male in
gender), the average of P2Y12 reaction unit (PRU) was 239.0±85.8 and the average
of inhibition was 0.29±0.22%. Distribution of P2Y12 reaction units (PRU) in this study
cohort was higher than Caucasian reports. Hyporesponders were defined as those with
PRU >275, which was derived from an ROC curve analysis. The background
characteristics were similar in both groups except for diabetes mellitus (DM) (higher
PRU vs. low PRU: 57% vs. 35%; p<0.05). The average PRU of patients with DM was
significantly higher than those without DM (273.7±70.7 vs. 213.2±87.8; p=0.005).
Patients with high PRU levels also had significantly higher rates of both the composite
events (2.4% vs. 0.8%, p=0.04), and stent thrombosis rate (1.8% vs. 0.2%; p=0.03)
compared to normal responders. Multivariable-adjusted analysis showed that PRU
>275 remains an independent predictor of the clinical composite endpoints.
Conclusion: Clopidogrel hypo-responsiveness was significantly associated with
cardiovascular outcome in patients undergoing elective PCI at 2 year. DM contributes
greatly to Asian populations’ platelet reactivity. We should consider ethnic differences
when choosing the cutoff value of PRU.
TCT-428
Effects of Low Dose Pioglitazone on Restenosis and Atheroma Plaques in
Patients with Diabetes Mellitus Undergoing Percutaneous Coronary
Intervention
Sung Gyu An1, Mi in Yang1, Hye won Lee1, Jun hyok Oh2, Jung hyun Choi2, Han
cheol Lee2, Kwang soo Cha2, Taek jong Hong2
1Department of Internal Medicine,Pusan National University Hospital, cardiology
fellow, Busan, Republic of Korea; 2professor, cardiology division, Department of
Internal Medicine,Pusan National University Hospital, busan, Republic of Korea
Background: The insulin-sensitizing agents (rosiglitazone, pioglitazone) reduced
neointimal proliferation in patients with diabetes mellitus (DM) who underwent
percutaneous coronary intervention (PCI) with bare metal stents via the PPAR-r
receptor. We evaluated the clinical outcomes, angiographic results and intravascular
ultrasound (IVUS) results of patients taking pioglitazone after PCI.
Methods: This study was a single center, prospective randomized study. The study
population currently included 121 diabetic patients with coronary artery disease,
assigned to 51 patients taking 15mg of low dose pioglitazone daily in addition to their
diabetic medications and 70 patients without pioglitazone. We have analyzed the
clinical outcomes, angiographic results, IVUS results and the effects on the lipid profile
after 12 months of treatment.
Results: Ninety-seven patients completed follow-up angiography. Among them,
follow-up IVUS was done in fifteen patients. There were no significant differences
between the pioglitazone group and the control group of the baseline clinical
demographics and angiographic findings. The average lesion length and reference
diameter (RD) were 27.2±10.8 mm vs. 27.9±13.2 mm and 2.61±0.46 mm vs. 2.67±0.43
mm in the pioglitazone group and the control group, respectively. After 12 months of
medication, total triglyceride and LDL levels were decreased in the pioglitazone group
compared to control group statistically insignificant. There was no difference of major
cardiac adverse events (MACE), TLR, TVR and The rate of in-stent restenosis(ISR)
between two groups. There were statistically no difference of neointimal volume,
percent neotintmal volume, percent atheroma volume and normalized total atheroma
volume between two groups on IVUS study.
Conclusion: The results of this study showed that low dose pioglitazone, in diabetic
patients who underwent PCI, was not associated with reduced MACE, TLR, non-TVR
and restenosis. And, low dose pioglitazone didn’t affect atheroma plaques and
neointimal proliferation in the stents by IVUS.
TCT-429
Clinical and Angiographic Results Of the Titanium vs Everolimus Stent In
Diabetic Patients Randomized Trial (TITANIC-XV)
Jose Ramon Lopez-Minguez1, Juan Manuel Nogales-Asensio1, Luis Javier Doncel
Vecino1, Maria Reyes Gonzalez Fernandez1, Francisco Pomar Domingo2, Pedro
Martinez Romero3, Jose Antonio Fernandez Diaz4, Jose Francisco Diaz Fernandez5,
Jose Moreu Burgos6, Antonio Merchan Herrera1, Gines Martinez Caceres1, Raul
Valdesuso Aguilar7, Pasi Karjalainen8
1Interventional Cardiology, Hospital Universitario Infanta Cristina, Badajoz, Spain;
2Hospital General de Valencia, Valencia, Spain; 3Hospital Puerto Real, Cadiz,
Spain; 4Hospital Puerta de Hierro, Madrid, Spain; 5Hospital Juan Ramon Jimenez,
Huelva, Spain; 6Hospital Virgen de la Salud, Toledo, Spain; 7Hospital Universitario
Virgen de la Arrixaca, Murcia, Spain; 8Satakunta Central Hospital, Pori, Finland
Background: In a roughly 25% of patients (p) Drug Eluting Stents (DES) are not
recommended due to specific clinical reasons that make prolonged use of clopidogrel
not appropriated. A remarkable percentage of these p have diabetes mellitus (DM), a
well known risk factor for stent restenosis. Our aim was to evaluate, in a prospective
randomized trial, whether in DM-p the titanium stent (T), a bioactive bare metal stent
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(BMS), could be a good alternative to everolimus DES (E).
Methods: All 173 p included, with a mean age of 65.5±9.5 years and a mean follow-
up of 510.3±228.9 days, were well balanced on basal variables. 1.6±0.8 lesions were
treated and 1.7±0.9 stents/p were implanted in both groups (mean diameter: 3.0± 0.4
mm; mean maximum length: 19.3±7.9 mm).
Results: A significant reduction in new revascularization rates was observed in E group
(18.1% vs 7.8%; p=0.04) but no significant differences were found for the other adverse
events or the composite major cardiac events. Insulindependent (ID) DM p subgroup
(50 p) randomized to T stent had a significantly greater incidence of new PCI (33.3%
vs 10.3%; p=0.04) and TVR (28.6% vs 6.9%; p=0.03). 9 months angiographic follow-
up was performed in 77 p. 131 lesions (L) were revised. Stent length was significantly
longer in E group (21.62±9.65 mm vs 18.72±5.53 mm; p=0.037). No differences were
found in the other basal and post-PCI angiographic variables.
Results of the quantitative coronary angiographic analysis in the angiographic
subgroup.
LLL: Late Luminal Lose.
Conclusion: Among global DM p, T stent behaviour was better than expected for a
non DES. Nonetheless, among ID-DM p E stent was superior to T stent. As expected,
E shows a significantly lower LLL than the T stent. However the LLL of the latter is
lower than that reported for other BMS and similar to that of some DES used until
recently.
TCT-430
Two Years Clinical Outcomes of Diabetic Patients Treated With a New
Generation Drug-Eluting Stent
Francesco Saia1, William Wijns2, Ran Kornowski3, Patrick Joly4, Fraser Witherow5,
Enrique Novo Garcia6, Dezsö Apró7, Ismail Ates8, Ernst G. Vester9, Petr Kala10,
Sinan Dagdelen11, Gian Battista Danzi12
1Policlinico S. Orsola Malpighi, Bologna, Italy; 2Cardiovascular Center OLV
Hospital, Aalst, Belgium; 3Rabin Medical Centre, Petah-Tikva, Israel; 4Polyclinique
du Parc Rambot, Aix en Provence Cedex 1, France; 5Dorset County Hospital,
Dorchester, United Kingdom; 6Hospital Guadelajara, Guadelajara, Spain; 7State
hospital for Cardiology, Balatonfüred, Hungary; 8Ozel Antalya Yasam hospital,
Sokak, Turkey; 9Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany;
10University Hospital, Brno, Czech Republic; 11Acibadem Hospital, Istanbul, Turkey;
12Ospedale Maggiore Policlinico, Milano, Italy
Background: Patients with diabetes have higher incidence of death, restenosis and
stent thrombosis as compared to non-diabetic patients. We investigated safety and
efficacy of a new DES, Nobori, in this complex patient population.
Methods: Of the 3067 consecutive patients treated with Nobori stent and enrolled in
the NOBORI2 multi-center study, 888 patients had diabetes mellitus (DM); 213 of
them were insulin dependent (IDDM). Primary endpoint was target lesion failure (TLF)
defined as cardiac death, target vessel related MI and target lesion revascularization
(TLR) at 1 year. Data were captured electronically and quality was extensively
monitored. An independent clinical event committee adjudicates all adverse events.
Results: Compared to non-DM patients, patients with DM had a significantly higher
frequency of hypertension, dyslipidemia and peripheral vascular disease. IDDM
patients had higher frequency of hypertension, congestive heart failure and previous
revascularization CABG than non-IDDM patients (p<0.05 for all). Moderate or severe
calcification was more frequent in lesions of patients with DM as well as vessel
tortuosity. Reference vessel diameter pre- and post-procedure was smaller in DM
patients. Post-procedure minimum lumen diameter in-stent and in-segment as well as
acute gain were also significantly smaller in DM patients. TLF rates at two years were:
7.2% in the DM group vs 4.2% in the non-DM group; p<0.001. There was a significant
difference in TLF rate between IDDM and non-IDDM patients (11.7% vs 5.8%;
p<0.006). In the DM group, 2.6% of patients died of a cardiac cause, 3.3% suffered
MI and 4.2% underwent TLR. The TLR rate between the IDDM and non-IDDM group
was significantly different (7.0% vs 3.3%; p<0.03). Stent thrombosis rate was 1.0% in
the DM group (0.9% in IDDM and 1.0% in NIDDM) and 0.7% in the non-DM group.
Conclusion: Clinical outcomes at 2 years after Nobori implantation in patients with
DM suggest that the DES is suitable for the treatment of this clinically complex patient
population. Particularly encouraging is the low rate of very late stent thrombosis up to
2 year follow-up.
TCT-431
Coronary Plaque Characteristics in Diabetic and Non-diabetic Patients
Evaluated by Integrated Backscatter Intravascular Ultrasound
Yoshinori Miyamoto, Hiroyuki Okura, Teruyoshi Kume, Terumasa Koyama,
Shinichiro Nezuo, Akihiro Hayashida, Yoji Neishi, Takahiro Kawamoto, Kiyoshi
Yoshida
Kawasaki Medical School, Kurashiki, Japan
Background: Patients with diabetes mellitus are known to be at increased risk for
acute coronary syndrome.The aim of this study was to examine plaque characteristics
of the diabetic patients with ischemic heart disease.
Methods: A total of 77 target lesions from 51 symptomatic ischemic heart disease
patients (26 diabetics and 25 non-diabetics) were enrolled. Intravascular ultrasound
(IVUS) imaging was performed before intervention. By gray scale IVUS, external
elastic membrane (EEM) cross-sectional area (CSA) and lumen CSA were measured.
Plaque plus media (P+M) CSA was calculated as EEM minus lumen CSA. Plaque
characteristics were further assessed by integrated backscatter (IB)-IVUS and classified
as follows: fibrosis, dense fibrosis, calcification and lipid pool. Thin-cap fibroatheroma
(TCFA) was defined as a lesion with confluent lipid plaque (≥ 55%) being directly in
contact with coronary lumen.
Results: Lesions in diabetic and non-diabetic patients had similar EEM, P+M and
lumen CSA. Lesions in diabetic patients had significantly higher % fibrosis area (47.7
± 11.4 vs. 39.5 ± 11.9 %, p = 0.01) and lower % lipid pool area (42.8 ± 15.1 vs. 53.9
± 17.4 %, p < 0.01) than those of non-diabetic patients. TCFA was less frequently
detected in diabetic than in non-diabetic patients 25 % vs. 49 %, p = 0.04).
Conclusion: Target lesions in diabetic patients had more fibrous and less lipid plaque
compared with non-diabetic patients. Plaque vulnerability of the diabetic patients may
not be determined based only on plaque characteristics.
TCT-432
Impaired Lung Function is an Independent Predictor of Type 2 Diabetes in
Korean Men: Five-year follow-up study
Ki-Chul Sung, Bum-Soo Kim
Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung
Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background: Impaired lung function, as measured by forced vital capacity (FVC) or
forced expiratory volume in one second (FEV1), has been reported as a significant
predictor of type 2 diabetes in Western countries . However, these previous, mostly
western, studies are limited because they largely focus on obese study populations
because obesity has been recognized to affect lung function. The aim of this study was
to assess the relationship between lung function and type 2 diabetes in Korean men
Methods: This study followed 9,220 men (mean age: 41.4 years, range: 24 to 82 years)
without type 2 diabetes at baseline over five years.
Results: The overall incidence of type 2 diabetes in the study populations was 2.2%
(207 of 9220 men). FVC and FEV1 were significantly and inversely associated with
the incidence of type 2 diabetes. In multivariable logistic regression analysis adjusting
for age, body mass index (BMI), education, smoking, exercise, alcohol, and
homeostasis model assessment of insulin resistance (HOMA-IR), the odds ratios (OR)
for type 2 diabetes (quartile 1 vs. quartile 4) were 1.90 (1.23-2.93) and 1.66 (1.10-
2.50) for FVC (% predicted) and FEV1 (% predicted), respectively (P=0.004 and
P=0.019). In non-obese subjects with BMI<25, quartile 1 of FVC (% predicted) and
FEV1 (% predicted) had significantly increased odds ratios (OR) for type 2 diabetes
compared with that of the highest quartile (quartile 4) after adjusting for age and BMI
(OR[95% CI], 2.15[1.02-4.57] and 2.19[1.09-4.42], P=0.045 and P=0.028,
respectively).
Conclusion: Impaired lung function as measured by FVC and FEV1 may be an
independent predictor of incident type 2 diabetes in relatively lean and previously
healthy Korean men.
TCT-433
Does Diabetes Mellitus Impact on Clinical Outcomes following Chronic Total
Occlusion Intervention with Drug-eluting Stents?
Amro Elnagar, Seung Woon Rha, Byoung Geol Choi, Sung Il Im, SunWon Kim, Jin
Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju
Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Korea University Guro Hospital, Seoul, Republic of Korea
Background: Patients (pts) with diabetes mellitus (DM) are at increased risk of
restenosis and other adverse cardiac events following percutaneous coronary
intervention (PCI). However, there have been limited data regarding the impact of DM
on major clinical outcomes following chronic total occlusion (CTO) intervention with
drug-eluting stents (DESs).
Methods: A total 277 consecutive pts who underwent PCI with DESs for CTO lesions
were enrolled for the study. Study population was divided into 2 groups; diabetic
(n=93) and non-diabetics (n=184). Baseline clinical characteristics, procedure related
complications and mid-term clinical outcomes were compared between the two groups.
Results: Baseline clinical characteristics were similar except that non-diabetics group
had more males (70.0% vs.67.7%, p=0.041), whereas diabetics had more hypertension
(73.1% vs.56.8%, p=0.008). No difference was found in procedure related
complications & one year major clinical outcomes between the two groups (Table).
B115JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Heart Disease in Diabetics
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
